Literature DB >> 25198529

TCR+CD4-CD8- T cells in antigen-specific MHC class I-restricted T-cell responses after allogeneic hematopoietic stem cell transplantation.

Raija K Ahmed1, Thomas Poiret, Aditya Ambati, Lalit Rane, Mats Remberger, Birgitta Omazic, Nalini K Vudattu, Jacek Winiarski, Ingemar Ernberg, Rebecca Axelsson-Robertson, Isabelle Magalhaes, Chiara Castelli, Olle Ringden, Markus Maeurer.   

Abstract

Human TCRαβ(+) CD4(-)CD8(-) double-negative (DN) T cells represent a minor subset in peripheral blood, yet are important in infectious diseases and autoimmune responses. We examined the frequency of DN T cells in 17 patients after allogeneic hematopoietic stem cell transplantation (aHSCT) at 1, 2, 3, 6, and 12 months post-aHSCT and show that these cells increase early after aHSCT and decrease with time after aHSCT. DN T cells reside in the terminally differentiated effector (CD45RA(+)CCR7(-)) T-cell population and are polyclonal, determined by T-cell receptor Vβ CDR3 analysis. Gene expression analysis of ex vivo sorted DN T cells showed a distinct set of gene expression, including interleukin-8, as compared with CD4(+) or CD8(+) T cells. DN T cells contributed to MHC class I-restricted EBV-directed immune responses, defined by antigen-specific cytokine production and by detection of HLA-A*02:01-restricted EBV BMLF-1 (GLCTLVAML), LMP-2A (CLGGLLTMV), and HLA-A*24:02-restricted EBV BRLF-1 (DYCNVLNKEF) and EBNA3 (RYSIFFDY)-specific T cells. We created retroviral-transfected Jurkat cell lines with a Melan-A/MART-1-specific TCR(+) and the CD8α chain to study TCR(+) DN T cells in response to their nominal MHC class I/peptide ligand. We show that DN T cells exhibit increased TCRζ chain phosphorylation as compared with the TCR(+)CD8(+) transgenic T-cell line. DN T cells contribute to antigen-specific T-cell responses and represent an effector T-cell population that may be explored in immunotherapeutic approaches against viral infections or transformed cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25198529     DOI: 10.1097/CJI.0000000000000047

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  5 in total

1.  Tumor-infiltrating lymphocytes (TILs) from patients with glioma.

Authors:  Zhenjiang Liu; Qingda Meng; Jiri Bartek; Thomas Poiret; Oscar Persson; Lalit Rane; Elena Rangelova; Christopher Illies; Inti Harvey Peredo; Xiaohua Luo; Martin Vijayakumar Rao; Rebecca Axelsson Robertson; Ernest Dodoo; Markus Maeurer
Journal:  Oncoimmunology       Date:  2016-11-29       Impact factor: 8.110

2.  Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning.

Authors:  Qin Li; Lalit Rane; Thomas Poiret; Jiezhi Zou; Isabelle Magalhaes; Raija Ahmed; Ziming Du; Nalini Vudattu; Qingda Meng; Åsa Gustafsson-Jernberg; Jacek Winiarski; Olle Ringdén; Markus Maeurer; Mats Remberger; Ingemar Ernberg
Journal:  Oncotarget       Date:  2016-05-24

3.  Double negative T cells mediate Lag3-dependent antigen-specific protection in allergic asthma.

Authors:  Dan Tian; Lu Yang; Song Wang; Yanbing Zhu; Wen Shi; Chunpan Zhang; Hua Jin; Yue Tian; Hufeng Xu; Guangyong Sun; Kai Liu; Zhongtao Zhang; Dong Zhang
Journal:  Nat Commun       Date:  2019-09-18       Impact factor: 14.919

4.  Markers of immune activation: novel biomarkers to predict the early-warning indicator of patients with papillary thyroid carcinoma.

Authors:  Hongsheng Lu; Lihong Zhang; Yuechu Dai; Yanyun Ruan; Xuequan Cao; Xiaobo Cai; Sihan Ruan; Qi Chen
Journal:  Diagn Pathol       Date:  2020-02-12       Impact factor: 2.644

Review 5.  Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications.

Authors:  Claudio Annaloro; Fabio Serpenti; Giorgia Saporiti; Giulia Galassi; Francesca Cavallaro; Federica Grifoni; Maria Goldaniga; Luca Baldini; Francesco Onida
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.